INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)

In the final overall survival analysis of the phase 3 INAVO120 trial, inavolisib in combination with palbociclib and fulvestrant demonstrated a statistically significant and clinically meaningful overall survival benefit compared with placebo plus palbociclib and fulvestrant among patients with PIK3CA-mutated, HR+ HER2- endocrine-resistant advanced breast cancer.